Opinion: Barring cisgender women from the Descovy trials was a bad call
Of the estimated 38 million people living with HIV around the world, more than half are women. Women, especially young women, are at greater risk for HIV infection than men.
So why would a company omit cisgender women from its clinical trials testing a pre-exposure prophylaxis (PrEP) regimen?
Read Original Article: Opinion: Barring cisgender women from the Descovy trials was a bad call »
